Zeto Receives US FDA 510(k) Clearance for Zeto New Wave to Advance Outpatient EEG

Why It Matters

Regulatory approval opens a fast‑growing market for portable EEG, reducing costs and improving patient access to brain monitoring outside traditional labs.

Key Takeaways

• FDA 510(k) clearance enables market entry in US
• 21 soft-tip electrodes cover full 10–20 system
• Recordings up to 2.5 hours for outpatient use
• Integrated video/audio and optional biosignals enhance diagnostics
• Portable design supports home and clinic EEG assessments

Pulse Analysis

The U.S. Food and Drug Administration’s 510(k) clearance of Zeto’s New Wave system marks a pivotal step for the outpatient electroencephalography (EEG) market. Historically, EEG recordings have been confined to hospital neurophysiology labs, limiting patient convenience and increasing costs. By meeting the FDA’s safety and efficacy standards, Zeto unlocks a pathway for clinics and even patients’ homes to capture high‑quality brain activity data. This regulatory milestone not only validates the technology but also signals growing demand for decentralized neurodiagnostic tools that can streamline care and reduce bottlenecks in specialty services.

New Wave distinguishes itself with a 21‑electrode soft‑tip array that adheres to the international 10–20 placement system, delivering full‑head coverage without the mess of traditional gel‑based caps. The lightweight acquisition unit synchronizes video and audio streams, enabling clinicians to correlate behavioral cues with electrophysiological events. Recordings can extend up to 2.5 hours, suitable for routine sleep, seizure, or event‑related potential studies, while optional channels—ECG, EOG, EMG, and photic stimulation detection—provide a multimodal snapshot of patient physiology. The plug‑and‑play design reduces set‑up time to minutes, a stark contrast to conventional setups that can exceed an hour.

For providers, the portable EEG platform promises faster turnaround, lower overhead, and the ability to reach underserved populations lacking access to tertiary neurocenters. Payers may view the reduced need for in‑person visits as a cost‑saving opportunity, potentially accelerating reimbursement adoption. Competitors such as Natus and BrainScope have introduced limited home‑EEG solutions, but Zeto’s comprehensive electrode array and integrated video give it a competitive edge. As tele‑neurology expands, New Wave positions Zeto to capture a growing share of the $1.2 billion US outpatient EEG market.